What it is: A stabilized fragment of human growth hormone engineered to trigger fat breakdown without raising IGF-1, affecting blood glucose, or producing the growth effects of full GH.
Research suggests: Strong selective fat reduction was demonstrated in multiple preclinical studies; early human trials provided a safety profile but Phase 3 development was never pursued.
Best for: Body composition and fat loss researchers
Key thing to know: Does not affect IGF-1 or blood glucose - a key distinction from full-length GH that makes it a cleaner research tool for studying isolated lipolytic mechanisms.
What is HGH Fragment 176-191?
HGH Fragment 176-191 is a synthetic peptide made of amino acids 176 through 191 of the human growth hormone (hGH) sequence, with a modification at position 176 to stabilize it. Researchers identified this region as the segment responsible for GH's fat-mobilizing (lipolytic) activity — distinct from the domains behind the anabolic and diabetogenic effects of full-length growth hormone.
The rationale for isolating this fragment was to create a compound capable of stimulating fat breakdown without triggering the insulin resistance, IGF-1 elevation, and tissue growth associated with exogenous GH administration. In preclinical studies, this selective activity was demonstrated, generating significant research interest among those studying metabolic interventions and body composition.
HGH Fragment 176-191 was developed and studied by Metabolic Pharmaceuticals in Australia, advancing to Phase 2 human clinical trials before the program was discontinued. It is not approved and is not commercially available as a pharmaceutical product. It exists as a research compound only.
How it works.
In research, the proposed mechanism has several parts.
The GH fragment: Full-length growth hormone drives lipolysis by binding GH receptors on adipocytes (fat cells), activating hormone-sensitive lipase and releasing stored fatty acids into circulation for energy. Research indicates this lipolytic signaling comes mainly from the C-terminal region of GH — the 176–191 fragment — while the anabolic and IGF-1-stimulating effects come from different structural regions.
Proposed mechanism: HGH Fragment 176-191 is proposed to act through a mechanism distinct from the main GH receptor — potentially a fragment-specific receptor or pathway favoring fat oxidation without upstream effects on the somatotropic axis. In rodent studies, it reduced fat mass, increased lean body mass relative to total body weight, and improved lipid profiles — effects attributed to selective lipolytic activity.
Preclinical evidence: Critically, studies in preclinical studies demonstrated that HGH Fragment 176-191 does not significantly affect blood glucose or insulin sensitivity, and does not produce measurable changes in IGF-1 levels - a key differentiating feature from exogenous GH. Whether this selectivity translates fully to human physiology at the doses studied remains an open research question.
What the research shows.
The research evidence breaks down as follows.
Animal research: Animal research - primarily in rodent models - provides the strongest evidence base for HGH Fragment 176-191. Studies consistently show selective fat reduction, preservation of lean mass, and absence of the insulin-desensitizing effects of full GH. These findings are reproducible and mechanistically coherent, generating legitimate scientific interest in the compound's metabolic applications.
Human data: Human data is limited, mainly the Phase 2 trials run by Metabolic Pharmaceuticals in the early 2000s. Those trials enrolled obese adults and showed modest reductions in body weight and fat mass versus placebo, without significant adverse effects. But they were small, the program stopped before Phase 3, and the full data was never peer-reviewed.
The limitation: This significantly limits the ability to draw firm conclusions about efficacy magnitude, optimal dosing, or long-term safety.
No large trials: No subsequent large human trials have been conducted. The evidence gap between promising animal data and confirmed human efficacy is the defining characteristic of this compound's research status, and is reflected in its preliminary rating.
Biomarkers to review first.
Research protocols for HGH Fragment 176-191 typically reference the following biomarkers as baseline context. Given its metabolic focus, understanding your current metabolic health markers is especially important before any protocol consideration.
What it's commonly researched with.
In research contexts, HGH Fragment 176-191 is frequently discussed alongside other metabolic peptides and GH secretagogues. The combinations below represent what researchers have studied - not recommendations for use.